AbCellera Biologics (NASDAQ:ABCL) Upgraded by Leerink Partnrs to Strong-Buy Rating

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) was upgraded by equities research analysts at Leerink Partnrs to a "strong-buy" rating in a note issued to investors on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for AbCellera Biologics' Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.64) EPS and FY2026 earnings at ($0.28) EPS.

Other analysts also recently issued reports about the company. Truist Financial cut their target price on AbCellera Biologics from $28.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, May 16th. KeyCorp increased their target price on AbCellera Biologics from $4.00 to $5.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Finally, Leerink Partners assumed coverage on AbCellera Biologics in a research note on Monday. They issued an "outperform" rating and a $5.00 price target for the company. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $7.50.

AbCellera Biologics Price Performance

Shares of AbCellera Biologics stock traded up $0.04 during trading on Monday, hitting $4.26. 3,971,238 shares of the company were exchanged, compared to its average volume of 3,465,253. AbCellera Biologics has a 1-year low of $1.89 and a 1-year high of $4.38. The firm has a market capitalization of $1.27 billion, a P/E ratio of -7.60 and a beta of 0.62. The firm's fifty day moving average price is $2.75 and its 200 day moving average price is $2.75.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.02. The firm had revenue of $4.24 million for the quarter, compared to analysts' expectations of $7.12 million. AbCellera Biologics had a negative return on equity of 15.98% and a negative net margin of 737.56%. As a group, equities research analysts anticipate that AbCellera Biologics will post -0.59 earnings per share for the current year.

Hedge Funds Weigh In On AbCellera Biologics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. DKM Wealth Management Inc. purchased a new position in shares of AbCellera Biologics in the 4th quarter worth about $29,000. Stratos Wealth Advisors LLC bought a new position in AbCellera Biologics during the 1st quarter valued at approximately $27,000. Janney Montgomery Scott LLC purchased a new position in shares of AbCellera Biologics during the 1st quarter worth approximately $29,000. Balyasny Asset Management L.P. purchased a new position in shares of AbCellera Biologics during the 4th quarter worth approximately $40,000. Finally, Mariner LLC purchased a new stake in shares of AbCellera Biologics in the 4th quarter worth approximately $42,000. 61.42% of the stock is currently owned by hedge funds and other institutional investors.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.